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Genome-Wide Association Study 
of Polymorphisms Predisposing to 
Bronchiolitis
Anu Pasanen1, Minna K. Karjalainen1, Louis Bont2, Eija Piippo-Savolainen3, 
Marja Ruotsalainen3, Emma Goksör4, Kuldeep Kumawat5, Hennie Hodemaekers6, 
Kirsi Nuolivirta7, Tuomas Jartti8, Göran Wennergren4, Mikko Hallman1, Mika Rämet1,9,* & 
Matti Korppi10,*
Bronchiolitis is a major cause of hospitalization among infants. Severe bronchiolitis is associated with 
later asthma, suggesting a common genetic predisposition. Genetic background of bronchiolitis is not 
well characterized. To identify polymorphisms associated with bronchiolitis, we conducted a genome-
wide association study (GWAS) in which 5,300,000 single nucleotide polymorphisms (SNPs) were tested 
for association in a Finnish–Swedish population of 217 children hospitalized for bronchiolitis and 778 
controls. The most promising SNPs (n = 77) were genotyped in a Dutch replication population of 416 
cases and 432 controls. Finally, we used a set of 202 Finnish bronchiolitis cases to further investigate 
candidate SNPs. We did not detect genome-wide significant associations, but several suggestive 
association signals (p < 10−5) were observed in the GWAS. In the replication population, three SNPs 
were nominally associated (p < 0.05). Of them, rs269094 was an expression quantitative trait locus 
(eQTL) for KCND3, previously shown to be associated with occupational asthma. In the additional 
set of Finnish cases, the association for another SNP (rs9591920) within a noncoding RNA locus was 
further strengthened. Our results provide a first genome-wide examination of the genetics underlying 
bronchiolitis. These preliminary findings require further validation in a larger sample size.
Bronchiolitis is a common lower respiratory infection (LRI) that primarily affects children under two years of 
age1,2. Respiratory syncytial virus (RSV) is recognized as the most important causative agent of bronchiolitis 
worldwide3. Typically, RSV epidemics occur in annual cycles and peak during the cold season in temperate cli-
mates and during the rainy season in warm climates4.
During RSV epidemics, most infants become infected and develop mild disease. However, a fraction of chil-
dren, between 2% and 3% of an age cohort, develop severe bronchiolitis that requires hospitalization5. RSV bron-
chiolitis is the most common infection-related cause of hospitalization among infants and young children in 
developed countries6. The only means of prevention is injecting high-risk children monthly with anti-RSV mon-
oclonal antibody7. There is no vaccine or effective antiviral therapy available for RSV infection. Thus, treatment of 
bronchiolitis is mainly supportive and includes supplying oxygen and maintaining hydration8.
There are several congenital and environmental risk factors, such as prematurity, immune deficiency, congeni-
tal heart disease, and tobacco smoke exposure, that predispose children to severe bronchiolitis4. However, the risk 
factors do not completely explain the variation in disease severity, and host genetic factors likely contribute to the 
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severity of viral bronchiolitis. Some evidence of genetic susceptibility was provided by a twin study that showed a 
higher concordance in hospitalization rates between identical twins than in fraternal twins9. That study estimated 
the heritability of bronchiolitis to be 22%.
Genetic studies of susceptibility to bronchiolitis have mostly focused on variants in selected candidate genes, 
often related to immunity. A few studies have evaluated the relevance of larger groups of genes and have linked 
variations in the severity of RSV disease with innate immunity–related genes and the IL13/IL4 locus in the 5q31 
cytokine cluster10,11. Moreover, genetic studies have demonstrated RSV bronchiolitis–associated loci in genes 
encoding proteins such as toll-like receptors (TLRs), surfactant protein D (SFTPD), Vitamin D receptor (VDR), 
and various cytokines, of which some have been suggested in more than one study3,10,12,13. However, most genetic 
associations have not been replicated in subsequent studies.
Severe viral bronchiolitis during childhood, especially after RSV bronchiolitis or rhinovirus bronchiolitis, is 
associated with the development of asthma later in life5,14. It is unknown whether the risk of asthma increases 
because of the bronchiolitis or whether a common genetic background underlies both diseases15. Polymorphisms 
in genes including IL-10, IL-13, TLR4, VDR, CCR5, and ADAM33 have been associated with both RSV bronchi-
olitis and a risk of asthma16,17. This may support a genetic predisposition to both infant viral bronchiolitis and 
subsequent asthma. An increased risk of childhood-onset asthma after rhinovirus infection has been associated 
with 17q21 locus18.
Regarding bronchiolitis, genetic associations suggested in different studies need to be validated in further 
studies. A more comprehensive characterization of genetic determinants will lead to improved recognition of risk 
groups and will likely contribute to the development of new and more-specific treatments for respiratory infec-
tions. Therefore, the aim of the present study was to conduct a hypothesis-free genome-wide association study 
(GWAS) to identify genetic polymorphisms that predispose infants to viral bronchiolitis.
Results
Suggestive associations in GWAS of bronchiolitis and RSV bronchiolitis. We detected several sug-
gestive association signals (p < 1 × 10−5) in the GWAS performed on 217 infants hospitalized for viral bronchi-
olitis and 778 controls. (Supplementary Figure S1). The stringent genome-wide significance level (p < 5 × 10−8) 
was not reached. Table 1 contains the results for the SNPs in the strongest suggestive GWA loci (p < 5 × 10−6). 
Cases were stratified according to presence of RSV, and RSV-positive bronchiolitis cases (n = 121) were tested 
against the same GWAS controls (“RSV GWAS”). Again, the signals did not reach the level of genome-wide sig-
nificance (p < 5 × 10−8) (Supplementary Figure S2). Table 2 lists the strongest suggestive GWA loci (p < 5 × 10−6) 
in the RSV GWAS. Three of the best loci were shared between the bronchiolitis GWAS and the RSV GWAS. The 
shared loci were situated in the regions near the genes VSTM4, C10orf71, and DRGX in chromosome 10 and in 
the region near LOC105375265 and LOC105375266 in chromosome 7. Based on the results obtained from the 
bronchiolitis GWAS and the RSV GWAS, we selected one representative SNP for the replication phase from each 
of the best suggestive GWA region. All SNPs selected for replication genotyping and the respective results are 
presented in Supplementary Table S1.
SNPs associated with RSV bronchiolitis in previous studies. We screened for SNPs that were 
reported to be associated with RSV bronchiolitis in previous studies and SNPs in the vicinity (within 20 kb) 
of such variants in our GWAS data. The exact SNPs reported in previous studies did not show associations or 
were not present in our GWAS data. The results for the variants near the reported bronchiolitis-associated SNPs 
are presented in Supplementary Table S2 (variants with p < 0.01 in the bronchiolitis GWAS or RSV GWAS are 
shown). The best SNP was rs56039226 in the CX3CR1 intron (p = 5.7 × 10−5). This SNP is located 11 kb upstream 
of the nonsynonymous CX3CR1 variant, rs3732378 (previously T280M). The A-allele–containing genotypes of 
rs3732378 were associated with RSV bronchiolitis severity in a previous study by Amanatidou et al.19. The exact 
SNP was present in our GWAS data, but it did not show an association (p = 0.095). However, the A-allele was also 
slightly more frequent in the GWAS cases compared to the controls (allele frequencies of 0.16 and 0.14 in cases 
and controls, respectively).
SNPs associated with asthma in previous studies. When we screened SNPs that have been reported 
to be associated with asthma in the NHGRI-EBI GWAS Catalog (with p ≤ 10−6), no associations were seen in our 
data. The best SNP was rs12436663 (p = 5.8 × 10−4, OR = 1.96 for T allele in RSV GWAS) within MRPP3 intron. 
The regions (20 kb) around the asthma-associated SNPs showed moderate signals in our data. The results are 
shown for variants with p ≤ 0.0001 in GWAS, RSV GWAS or GWAS with cases < 1year (Supplementary Table S3). 
Many of the variants are known eQTLs. The variants showing strongest suggestive signals were in the area of 
VCAN, HLA-DQA1, and NIN. Those genes have various roles including cell adhesion, cytokine production, anti-
gen binding and GTP binding20.
Associations of rs269094, rs9591920, and rs1537091 with bronchiolitis in the replication 
populations. In the replication phase, we analyzed 77 of the most promising SNPs based on the results of 
the GWA analysis in an independent population collected in the Netherlands (416 cases and 432 controls). The 
suggestive associations of three of the SNPs (rs269094, rs9591920, and rs1537091) with bronchiolitis were nom-
inally replicated (p < 0.05), and meta-analysis for these SNPs yielded lower p values compared to the original 
GWAS (Table 3). The results were similar for the RSV GWAS and GWAS of infants aged < 1 year. The results for 
the SNPs with a p value < 0.1 in the Dutch population and ORs in the same direction in the GWAS subsets, and 
meta-analyses, are shown in Supplementary Table S4.
To identify genes for which expression is potentially affected by our candidate SNPs (p value < 0.05 in the 
Dutch replicate), we queried genotype-tissue expression (GTEx) data21. Rs269094 was previously identified as 
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an eQTL for KCND3 in spleen (p = 7.1 × 10−10); the C-allele is associated with higher expression. Another corre-
lated SNP in the same region (rs269101, r2 = 0.42 in 1000 genomes phase3 Finnish individuals) showed a trend 
toward association in our GWAS (p = 4.2 × 10−5) and in the replicate (p = 0.054), further supporting the result. 
By exploring the NHGRI-EBI GWAS Catalog, we also discovered that variants in or near KCND3 have been asso-
ciated with diisocyanite-induced asthma and the cytokine response to smallpox22. The two other candidate SNPs 
were not identified as known eQTLs.
We further screened the three SNPs (with p < 0.05 in the Dutch population) in the Finnish case data collected 
in Turku, using the NordicDB population controls as a reference (Supplementary Table S5). Rs9591920 showed 
an association (p = 0.042, OR = 1.5). The allele frequencies of the two other SNPs, rs269094 and rs1537091, did 
not differ between cases and controls in this analysis.
Suggestive GWA locus ╤ Selected SNP information
Chr Range Ж
Span 
(kb) SNPs Lowest p SNP name LocationЖ Genes** A1
MAF OR‡ (95% 
CI) pCases  Controls
1 246851155..246968053 116 119 3.2 × 10−6 rs61202512 246860213 SCCPDH, CNST A 0.464 0.327 1.67 (1.32–2.11) 1.6 × 10
−5
2 235168096..235202022 33 29 2.8 × 10−6 rs11886348 235193436 LOC105373933 G 0.079 0.027 3.35 (2.02–5.55) 2.8 × 10
−6
3 5377711..5570764 193 24 4.7 × 10−6 rs79062720 5442550 MIR4790, EDEM1 C 0.064 0.021 3.79 (2.14–6.70) 4.7 × 10
−6
3 39318192..39593234 275 38 3.2 × 10−6 rs56039226 39318192 CX3CR1 A 0.041 0.011 4.43 (2.15–9.14) 5.7 × 10
−5
3 107206802..107233889 27 6 3.0 × 10−6 rs6437736 107208688 BBX, CCDC54 A 0.366 0.491 0.58 (0.47–0.73) 3.0 × 10
−6
3 153780474..153973898 193 9 5.0 × 10−6 rs36086140 153973898 ARHGEF26 T 0.093 0.037 2.86 (1.82–4.48) 5.0 × 10
−6
4 24735463..24736258 0.8 2 2.6 × 10−6 rs4697072 24735463 SOD3, CCDC149 G 0.410 0.532 1.77 (1.40–2.25) 2.6 × 10
−6
5 167829645..168048306 218 6 6.0 × 10−7 rs4976604 167849667 WWC1 C 0.064 0.021 3.80 (2.15–6.71) 4.3 × 10
−6
7 46319511..46524796† 205 9 1.5 × 10−7 rs62452699 46492326 LOC105375265, LOC105375266 T 0.143 0.060 2.83 (1.92–4.17) 1.5 × 10
−7
10 50452677..50460878† 8 10 4.9 × 10−7 rs17009617 50453933 VSTM4, C10orf71 A 0.090 0.032 3.39 (2.11–5.46) 4.9 × 10
−7
10 50454331..50553085† 98 50 3.9 × 10−7 rs76728164 50465201 C10orf71, DRGX T 0.088 0.032 2.93 (1.86–4.62) 3.7 × 10
−6
10 50454331..50553085† 98 50 3.9 × 10−7 rs1001338 50498449 C10orf71, DRGX G 0.086 0.031 3.10 (1.95–4–93) 1.7 × 10
−6
10 128584158..128805211 221 12 2.1 × 10−6 rs111255454 128777619 DOCK1 G 0.065 0.021 3.90 (2.22–6.84) 2.1 × 10
−6
12 17376616..17514609 137 37 3.8 × 10−6 rs2137526 17377995 LOC105369677, LOC105369676 T 0.233 0.148 1.98 (1.48–2.65) 3.8 × 10
−6
13 59304857..59481192 176 40 2.0 × 10−6 rs9591920 59315119 LOC105370220 T 0.190 0.098 2.16 (1.57–2.97) 2.0 × 10
−6
13 67847391..67877199 29 4 4.6 × 10−7 rs142670120 67850108 PCDH9, LOC105370246 DEL 0.099 0.037 3.23 (2.05–5.10) 4.6 × 10
−7
16 73130946..73140092 9 5 2.4 × 10−6 rs76079505 73136490 ZFHX3, C16orf47 T 0.203 0.100 2.22 (1.59–3.09) 2.4 × 10
−6
17 72973962..73220824 246 12 2.1 × 10−6 rs113409681 72973962 HID1, CDR2L A 0.076 0.025 3.58 (2.11–6.05) 2.1 × 10
−6
20 56486748..56527179 40 12 1.3 × 10−6 rs379083* 56527179 MIR4532, LOC100129869 T 0.112 0.043 2.82 (1.86–4.29) 1.3 × 10
−6
21 42284256..42343366 59 52 2.6 × 10−6 rs117674297 42343366 DSCAM, BACE2 A 0.092 0.038 2.96 (1.88–4.65) 2.6 × 10
−6
Table 1.  Strongest suggestive GWA loci (p < 5 × 10−6) identified by bronchiolitis GWAS and SNPs 
selected for replication genotyping from each locus. ╤Each suggestive GWA locus comprises several SNPs  
in LD (r2 > 0.5, p < 0.01). Loci were formed with default options of LD-based result clumping (PLINK 1.9). We  
selected one variant for replication genotyping from each locus. Signals in sporadic imputed variants (not shown)  
were considered unreliable and not chosen for replication genotyping. Variants with a minor allele frequency of  
< 0.02 within either cases or controls were not chosen for replication genotyping. ЖRange and location refer to 
human genome build 37 (GRCh37/hg19) coordinates. **Corresponding locus shown for variants within genes; two 
nearest loci shown for intergenic SNPs. ‡OR for A1 allele under additive model in logistic regression, with sex and 
three principal components as covariates. †Suggestive GWA loci shared between GWAS and RSV GWAS (of loci 
with p < 5 × 10−6). GWA, genome-wide association; SNP, single nucleotide polymorphism; Chr, chromosome; MAF, 
minor allele frequency; OR, odds ratio; CI, confidence interval; LD, linkage disequilibrium.
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Discussion
In the present study, we identified several suggestive GWA loci associated with viral bronchiolitis. Three of the 
SNPs selected for replication genotyping showed nominal associations (p < 0.05) also in an external replication 
population. Of those variants, rs269094 is a known eQTL for KCND3, which has been linked to diverse functions 
including regulation of neurotransmitter release and heart rate20. More recently, the gene has also been associ-
ated with diisocyanite-induced occupational asthma and cytokine response in smallpox vaccine recipients23,24. 
At the protein level, KCND3 interacts with another membrane protein, DPP10, of which genetic variants have 
been associated with conditions including asthma20,25. The association of another SNP with p < 0.05 in the Dutch 
population, rs9591920, was nominally replicated in the additional Finnish case set. The variant resides within an 
uncharacterized noncoding RNA (ncRNA) locus (LOC105370220)20. Thus, it is difficult to assign potential func-
tions to this region. In general, intergenic or noncoding SNPs have been associated with many complex pheno-
types in previous GWASs. The SNPs within ncRNA loci could affect either the expression or function of the RNA 
molecule, which may further regulate target gene expression26. The third variant showing nominal association 
in the Dutch cohort, rs1537091, is located in an intergenic region, nearest loci being long intergenic non-protein 
coding RNAs without known function. Further study is required to validate the associations of our candidate 
variants and study their potential mechanism in bronchiolitis susceptibility.
We detected only modest signals for the regions around SNPs reported by previous studies to be associated 
with bronchiolitis. This might be due to allele frequency or LD structure differences among study populations, 
false discoveries by chance due to limited population size or gene-environment interactions. The confounding 
effect of population stratification is difficult to take into account in candidate gene studies; in the present study, 
we could account for the slight structure caused by differing genetic origins by exploiting the genome-wide data 
and principal components and thus reduce the risk of false-positive findings. Further, we could exclude popula-
tion outliers and close relatives based on information provided by genome-wide sampling. In our data, the best 
variant near the SNP that was previously reported to be associated with bronchiolitis was in CX3CR1 intron 
(p = 5.7 × 10−5).
Suggestive RSV GWA locus╤ Selected SNP information
Chr RangeЖ
Span 
(kb) SNPs Lowest p SNP name LocationЖ Genes** A1
MAF OR‡ (95% 
CI) pCases Controls
1 153512691..153996110 483 6 5.2 × 10−7 rs75940909 153932075 SLC39A1 A 0.063 0.011 5.58 (2.69–11.93) 9.2 × 10
−6
1 154011426..154260767 249 4 1.1 × 10−6 rs186841738 154187935 C1orf43 A 0.062 0.009 6.73 (3.02–15.01) 3.1 × 10
−6
2 36592600..36617435 24 2 2.4 × 10−6 rs112913823 36617435 CRIM1 G 0.086 0.025 4.38 (2.37–8.09) 2.4 × 10
−6
3 185675973..185677613 1 9 4.9 × 10−6 rs6444089 185676350 TRA2B, ETV5 G 0.277 0.410 0.48 (0.34–0.66) 8.7 × 10
−6
3 185675973..185677613 1 9 4.9 × 10−6 rs55675198 185677613 TRA2B, ETV5 G 0.252 0.391 0.46 (0.33–0.64) 6.2 × 10
−6
4 32653789..32869901 216 52 4.7 × 10−6 rs4547837 32688632 LOC107986223, LOC101927363 T 0.054 0.010 6.55 (2.93–14.65) 4.7 × 10
−6
7 46319511..46524796† 205 9 6.9 × 10−7 rs62452699 46492326 LOC105375265, LOC105375266 T 0.149 0.061 3.37 (2.09–5.45) 6.9 × 10
−7
7 148765688..148959272 193 21 5.5 × 10−7 rs139743624 148870713 ZNF398 A 0.051 0.010 6.51 (2.86–14.86) 8.5 × 10
−6
10 50452677..50460878† 8 10 3.1 × 10−7 rs17009617 50453933 VSTM4, C10orf71 A 0.111 0.032 4.16 (2.41–7.19) 3.1 × 10
−7
10 50454331..50553085† 98 50 1.2 × 10−7 rs76728164 50465201 C10orf71, DRGX T 0.106 0.033 3.46 (2.05–5.85) 3.6 × 10
−6
10 50454331..50553085† 98 50 1.2 × 10−7 rs1001338 50498449 C10orf71, DRGX G 0.112 0.031 3.95 (2.33–6.69) 3.6 × 10
−7
15 39354517..39515134 160 46 6.5 × 10−7 rs75360543 39505815 LOC105370777 G 0.104 0.034 4.10 (2.35–7.14) 6.5 × 10
−7
Table 2.  Strongest suggestive GWA loci (p < 5 × 10−6) from RSV bronchiolitis GWAS and SNPs selected 
for replication genotyping from each locus. ╤Each suggestive GWA locus comprises several SNPs in LD 
(r2 > 0.5, p < 0.01). Loci were formed with default options of LD-based result clumping (PLINK 1.9). We 
selected one variant for replication genotyping from each locus. Signals in sporadic imputed variants (not 
shown) were considered unreliable and not chosen for replication genotyping. ЖRange and location refer 
to human genome build 37 (GRCh37/hg19) base pair positions. **Corresponding locus shown for variants 
within genes; two nearest genes shown for intergenic SNPs. ‡OR for A1 allele under additive model in logistic 
regression, with sex and three principal components as covariates. †Suggestive GWA loci shared between GWAS 
and RSV GWAS (of loci with p < 5 × 10−6). GWA, genome-wide association; RSV, respiratory syncytial virus; 
SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, 
confidence interval; LD, linkage disequilibrium.
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Due to suggested shared genetic contribution among bronchiolitis and asthma, variants that have been 
associated with asthma in previous studies, and regions (20 kb) around the variants, were screened in our data. 
Moderate signals (p < 0.0001) were detected in variants within genes including VCAN and HLA-DQA1. HLA-DQ 
region has been associated with different types of asthma in several studies27, and an association of VCAN with 
asthma was discovered more recently28. Asthma clusters in families and likely has a strong genetic component, 
with heritability estimates as high as 60%29. Hundreds of genetic polymorphisms have been associated with dif-
ferent asthma phenotypes in past genetic studies. However, asthma is a complex and heterogeneous disease which 
is likely contributed by a combination of many genes in interaction with environmental factors30. Thus, the poten-
tial roles of the suggested genes in LRI susceptibility, and an overlap with biological pathways related to asthma, 
warrant further study.
The present study had several limitations. The sample size was relatively small, and thus especially the strati-
fied GWAS subset analyses might have been underpowered. In the discovery GWAS, the best suggestive associa-
tion signals, that were almost genome-wide significant, were seen in the area of LOC105375265 on chromosome 
7 and in the area of VSTM4 and DRGX on chromosome 10. The signals in these regions were identified both in 
the GWAS and the RSV GWAS but not in the Dutch replication population. Despite the lack of replication, these 
signals might well reflect true associations in the Finnish population.
There is no worldwide consensus on treatment and diagnosis of bronchiolitis. The American Academy of 
Pediatrics defines 24 months as an upper age limit of bronchiolitis2,31. In Finland and Sweden, clinicians have 
begun to consider bronchiolitis to be mainly a disease of infants under 12 months of age32. In our GWAS, most 
of the cases were < 12 months of age at the time of the diagnosis. Moreover, for the most part the results for the 
GWAS < 1 year were similar to those of the main GWAS. However, the differing clinical definitions of included 
bronchiolitis cases were one limitation of the current study. Further limitation was the differing proportion of 
RSV positive samples between the GWAS and the replication populations. In studies to come, selecting bronchi-
olitis study cases according to more specified criteria will likely help detecting greater effects and susceptibility 
genes associated with specific phenotypes.
The present GWAS identified several variants that were suggestively associated with bronchiolitis. Although 
no significant associations were detected, our study provides the first genome-wide examination of bronchiolitis 
and a large body of data that may benefit future studies on complex genetic determinants and biological pathways 
that cause variation in bronchiolitis susceptibility. Further replication and functional validation is needed to ver-
ify and uncover the potential roles of our candidate SNPs. The relationship between infant viral bronchiolitis and 
asthma, and a plausible genetic overlap of the two diseases, remain an important area of study.
Materials and Methods
Study design and populations. The study populations comprised a total of 2045 study subjects consisting 
of 835 bronchiolitis cases and 1210 controls (974 females and 1071 males). The study was approved by the ethics 
committees of Tampere University Hospital and Kuopio University Hospital, Finland, and the regional ethics 
committee of Gothenburg, Sweden. The study was carried out in accordance with the approved guidelines of the 
WMA Declaration of Helsinki. Informed consents were obtained from the study subjects or provided by their 
parents. The main elements of the study were: (1) a GWAS in a Finnish–Swedish discovery population of 217 
cases and 778 controls, (2) an analysis of the most promising variants in a Dutch replication population of 416 
cases and 432 controls, and (3) a further examination of the most promising variants in an additional Finnish set 
of 202 cases. Moreover, GWAS cases were stratified according to age or presence of RSV and the subgroups of 
RSV positive cases (“RSV GWAS”) and those of < 12 months of age were studied separately (Fig. 1).
The inclusion criteria for all the affected children were (1) clinically diagnosed bronchiolitis, (2) an age < 24 
months at the time of diagnosis and (3) native Finnish, Swedish or Dutch ethnicity. Bronchiolitis was defined as 
the presence of LRI and respiratory symptoms typical of bronchiolitis, including wheezing and labored breath-
ing2. RSV infection was tested by antigen immunofluorescent or radioimmuno assays, viral isolation, PCR of 
nasopharyngeal cells or by serum antibody assays.
Overall, RSV was detected in 72% of the cases, and > 80% were under 12 months of age. Characteristics 
of bronchiolitis cases in GWAS discovery cohorts and validation cohorts are presented in Tables 4 and 5. The 
Variant details GWAS Replication Meta-analysis§
SNP Chr LocationЖ Genes** A1 OR‡ (95% CI) p OR╤ (95% CI) p OR (95% CI) p
rs269094 1 112639174 KCND3, LOC643355 C 1.67 (1.30–2.15) 5.3 × 10−5 1.28 (1.03–1.60) 0.0292 1.44 (1.22–1.70) 1.5 × 10−5
rs9591920 13 59315119 LOC105370220 T 2.16 (1.57–2.97) 2.0 × 10−6 1.41 (1.05–1.88) 0.0227 1.71 (1.38–2.12) 9.8 × 10−7
rs1537091 21 29004226 LOC105372763, LINC00113 A 1.69 (1.34–2.14) 1.3 × 10−5 1.24 (1.01–1.52) 0.0408 1.42 (1.21–1.66) 1.1 × 10−5
Table 3.  SNPs that had a p value of <0.05 in the Dutch replicate, with ORs in the same direction compared 
to GWAS. ЖLocation refers to human genome build 37 (GRCh37/hg19) coordinates. **Corresponding locus 
shown for variants within genes; two nearest genes shown for intergenic SNPs. ‡OR for A1 allele under additive 
model in logistic regression, with sex and three principal components as covariates. ╤OR for A1 allele under 
additive model in logistic regression, with sex as a covariate. §Meta-analysis performed under fixed-effects 
model for logistic regression result files of discovery and replication data. SNP, single nucleotide polymorphism; 
GWAS, genome-wide association study; RSV, respiratory syncytial virus; OR, odds ratio; CI, confidence 
interval; Chr, chromosome.
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populations are further described in the Supplementary Material. Briefly, the Finnish individuals (n = 936) in the 
GWAS discovery population originated from Kuopio (64 cases, 64 controls), Tampere (124 cases), and Helsinki/
Kuopio (684 controls) regions33–36. A subset of the GWAS population was collected in Gothenburg, Sweden (29 
cases, 30 controls)37. Replication cohorts originated from The Netherlands (n = 848) and Finland (n = 202)10,38,39.
DNA sample preparation and genotyping. Genomic DNA was obtained from whole blood samples, 
buccal swabs, or buffy coats. DNA from blood samples collected from the GWAS subjects was extracted with 
the UltraClean® Blood DNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA, USA). DNA from infants 
in the Dutch replication cohort was isolated from blood samples or buccal swabs with the QIAamp DNA Blood 
Kit (Qiagen, Hilden, Germany). DNA extraction from buffy coats collected from the Dutch population controls 
was done by digestion with proteinase K followed by salting out with potassium acetate and chloroform–isoamyl 
alcohol extraction.
Genome-wide genotyping was performed with the Human Genotyping Array Kits (Illumina, San Diego, CA, 
USA. (Supplementary Table S6). The Technology Centre at the Institute for Molecular Medicine Finland (FIMM), 
University of Helsinki, did the genotyping. FIMM also performed the targeted SNP genotyping in the replication 
phase with the Sequenom iPLEX Gold assay (San Diego, CA, USA). NordicDB controls are described in detail in 
Bilguvar et al.40.
Quality control and imputation of the genome-wide data. After quality control (QC), 995 study 
subjects were available for the analyses: 464 male subjects and 531 female subjects/217 cases and 778 controls. 
There were 79,563 autosomal SNPs with a MAF of > 0.01. The data was prephased with SHAPEIT2, followed by 
genotype imputation (i.e., statistical prediction of missing genotypes) with IMPUTE241,42. More detailed descrip-
tion of the QC and imputation can be found in the online Supplementary Material. After imputation, the amount 
of SNPs (MAF > 0.01) was 5,304,323.
Selection of SNPs for replication analysis. Seventy-seven SNPs were genotyped in the Dutch replication 
population. Because the stringent genome-wide significance level (p < 5 × 10−8) was not reached in the discovery 
GWAS, less-strict criteria were applied for the selection of SNPs. p values of < 5 × 10−4 and < 1 × 10−4 for gen-
otyped and imputed SNPs, respectively, were used as threshold values for suggestive associations. For imputed 
SNPs, linkage disequilibrium (LD) was taken into account by selecting relatively independent (r2 < 0.5) SNPs 
from each suggestive GWA locus. Sporadic imputed SNPs were excluded. Provided that a suggestive GWA locus 
had several variants with similar p values, the best SNP was chosen based on predicted or empirical regulatory 
functions (including eQTLs, promoter activity, and protein binding sites) by exploring annotation databases, 
including HaploReg v. 4.1, GTEx, and dbSNP21,43,44. We did not choose low-frequency SNPs (MAF < 0.02 in cases 
or controls) in the main GWAS population to avoid genotyping monomorphic SNPs in the Dutch population. 
Figure 1. Flow chart of study design and populations. Primary endpoint studied in GWAS was viral 
bronchiolitis. Cases were further stratified into subsets according to presence of RSV and age. Stratified 
phenotypes studied were bronchiolitis caused by respiratory syncytial virus (“RSV GWAS”) and bronchiolitis in 
infants < 12 months of age.
All Kuopio, FIN Tampere, FIN Gothenburg, SWE
n % n % n % n %
All cases 217 100% 64 100% 124 100% 29 100%
RSV positive 121 56% 21 33% 90 73% 10 36%
RSV negative 94 43% 41 64% 34 27% 19 64%
Age < 12 months 173 80% 33 52% 124 100% 16 55%
Age > 12 months 42 19% 29 45% 0 0% 13 45%
Males 114 53% 36 56% 62 50% 16 55%
Hospitalization rate 100% 100% 100% 100%
Table 4.  Characteristics of study cases in GWAS bronchiolitis populations. GWAS, genome-wide 
association study; FIN, Finland; SWE, Sweden.
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We tested the homogeneity of odds ratios among the GWAS subpopulations according to city of origin with the 
Breslow–Day test and excluded variants with p values of < 0.01.
Statistical analysis. Principal component analysis (PCA). PCA with PLINK1.9 was performed on nonim-
puted LD-pruned GWAS data to delineate components explaining possible remaining population structure. The 
adequate number of components was evaluated based on genome-wide inflation factor lambda (λ ), eigenvalues, 
and inspection of covariate significances in logistic regression. Three leading components were incorporated into 
subsequent association analyses.
SNP association analysis. Allele frequency differences were assessed with logistic regression under an addi-
tive model, with gender and three principal components as covariates. Analyses were performed with PLINK 
1.945. Lambda values were close to 1, indicating an adequately controlled population structure (λ = 1.004 for the 
genotyped population, λ = 1.06 for the imputed population). In the RSV GWAS, we studied a subset of cases 
positive for RSV infection (n = 121) against the GWAS controls (n = 778). Similarly, cases that were < 12 months 
of age (173 cases, 778 controls) were tested as a group. Replication populations collected in the Netherlands 
and Turku, Finland, were studied with logistic regression analysis under an additive model, with gender as a 
covariate. Measures of basic QC, which entailed removing variants with MAF < 0.01, genotyping rate < 0.9, or 
deviation from HWE (p < 0.001), were performed. The replication case set of Turku was studied against the 
NordicDB population controls (n = 684). The discovery and the Dutch replication population were studied by 
meta-analysis under a fixed-effects model to estimate their combined effect. Confidence intervals for odds ratios 
of meta-analysis were calculated with a meta package in R46,47. Finally, SNPs that were reported in the literature 
to be associated with RSV bronchiolitis or asthma, or variants within 20 kb of such SNPs, were screened in our 
GWAS data.
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